vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and ESCO TECHNOLOGIES INC (ESE). Click either name above to swap in a different company.
ESCO TECHNOLOGIES INC is the larger business by last-quarter revenue ($289.7M vs $183.1M, roughly 1.6× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 9.9%, a 3.4% gap on every dollar of revenue. On growth, ESCO TECHNOLOGIES INC posted the faster year-over-year revenue change (17.3% vs -1.8%). ESCO TECHNOLOGIES INC produced more free cash flow last quarter ($63.0M vs $24.6M). Over the past eight quarters, ESCO TECHNOLOGIES INC's revenue compounded faster (7.8% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Esco is a Singaporean brand that develops, manufactures, and sells products and services for laboratories.
AMPH vs ESE — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $289.7M |
| Net Profit | $24.4M | $28.7M |
| Gross Margin | 46.8% | 41.4% |
| Operating Margin | 19.4% | 13.2% |
| Net Margin | 13.3% | 9.9% |
| Revenue YoY | -1.8% | 17.3% |
| Net Profit YoY | -35.7% | 22.2% |
| EPS (diluted) | $0.51 | $1.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $289.7M | ||
| Q3 25 | $191.8M | $286.5M | ||
| Q2 25 | $174.4M | $296.3M | ||
| Q1 25 | $170.5M | $265.5M | ||
| Q4 24 | $186.5M | $247.0M | ||
| Q3 24 | $191.2M | $298.5M | ||
| Q2 24 | $182.4M | $260.8M | ||
| Q1 24 | $171.8M | $249.1M |
| Q4 25 | $24.4M | $28.7M | ||
| Q3 25 | $17.4M | $218.7M | ||
| Q2 25 | $31.0M | $26.1M | ||
| Q1 25 | $25.3M | $31.0M | ||
| Q4 24 | $38.0M | $23.5M | ||
| Q3 24 | $40.4M | $34.3M | ||
| Q2 24 | $37.9M | $29.2M | ||
| Q1 24 | $43.2M | $23.2M |
| Q4 25 | 46.8% | 41.4% | ||
| Q3 25 | 51.4% | 45.9% | ||
| Q2 25 | 49.6% | 41.2% | ||
| Q1 25 | 50.0% | 41.1% | ||
| Q4 24 | 46.5% | 39.8% | ||
| Q3 24 | 53.3% | 40.1% | ||
| Q2 24 | 52.2% | 39.6% | ||
| Q1 24 | 52.4% | 38.8% |
| Q4 25 | 19.4% | 13.2% | ||
| Q3 25 | 13.2% | 17.2% | ||
| Q2 25 | 24.2% | 11.2% | ||
| Q1 25 | 21.9% | 15.3% | ||
| Q4 24 | 24.2% | 11.4% | ||
| Q3 24 | 29.8% | 14.8% | ||
| Q2 24 | 30.3% | 14.3% | ||
| Q1 24 | 27.9% | 11.7% |
| Q4 25 | 13.3% | 9.9% | ||
| Q3 25 | 9.0% | 76.3% | ||
| Q2 25 | 17.8% | 8.8% | ||
| Q1 25 | 14.8% | 11.7% | ||
| Q4 24 | 20.4% | 9.5% | ||
| Q3 24 | 21.1% | 11.5% | ||
| Q2 24 | 20.8% | 11.2% | ||
| Q1 24 | 25.1% | 9.3% |
| Q4 25 | $0.51 | $1.11 | ||
| Q3 25 | $0.37 | $8.43 | ||
| Q2 25 | $0.64 | $1.01 | ||
| Q1 25 | $0.51 | $1.20 | ||
| Q4 24 | $0.74 | $0.91 | ||
| Q3 24 | $0.78 | $1.32 | ||
| Q2 24 | $0.73 | $1.13 | ||
| Q1 24 | $0.81 | $0.90 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $103.8M |
| Total DebtLower is stronger | $608.7M | $145.5M |
| Stockholders' EquityBook value | $788.8M | $1.6B |
| Total Assets | $1.6B | $2.4B |
| Debt / EquityLower = less leverage | 0.77× | 0.09× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $103.8M | ||
| Q3 25 | $276.2M | $101.3M | ||
| Q2 25 | $231.8M | $78.7M | ||
| Q1 25 | $236.9M | $57.4M | ||
| Q4 24 | $221.6M | $71.3M | ||
| Q3 24 | $250.5M | $66.0M | ||
| Q2 24 | $217.8M | $63.0M | ||
| Q1 24 | $289.6M | $59.4M |
| Q4 25 | $608.7M | $145.5M | ||
| Q3 25 | $608.6M | $186.0M | ||
| Q2 25 | $607.7M | $525.0M | ||
| Q1 25 | $603.9M | $88.0M | ||
| Q4 24 | $601.6M | $112.0M | ||
| Q3 24 | $596.4M | $122.0M | ||
| Q2 24 | $586.9M | $173.0M | ||
| Q1 24 | $594.0M | $191.0M |
| Q4 25 | $788.8M | $1.6B | ||
| Q3 25 | $776.7M | $1.5B | ||
| Q2 25 | $757.5M | $1.3B | ||
| Q1 25 | $751.3M | $1.3B | ||
| Q4 24 | $732.3M | $1.2B | ||
| Q3 24 | $727.7M | $1.2B | ||
| Q2 24 | $713.3M | $1.2B | ||
| Q1 24 | $672.4M | $1.2B |
| Q4 25 | $1.6B | $2.4B | ||
| Q3 25 | $1.7B | $2.4B | ||
| Q2 25 | $1.6B | $2.5B | ||
| Q1 25 | $1.6B | $1.8B | ||
| Q4 24 | $1.6B | $1.8B | ||
| Q3 24 | $1.5B | $1.8B | ||
| Q2 24 | $1.5B | $1.8B | ||
| Q1 24 | $1.6B | $1.8B |
| Q4 25 | 0.77× | 0.09× | ||
| Q3 25 | 0.78× | 0.12× | ||
| Q2 25 | 0.80× | 0.40× | ||
| Q1 25 | 0.80× | 0.07× | ||
| Q4 24 | 0.82× | 0.09× | ||
| Q3 24 | 0.82× | 0.10× | ||
| Q2 24 | 0.82× | 0.14× | ||
| Q1 24 | 0.88× | 0.16× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $68.9M |
| Free Cash FlowOCF − Capex | $24.6M | $63.0M |
| FCF MarginFCF / Revenue | 13.4% | 21.7% |
| Capex IntensityCapex / Revenue | 4.5% | 2.0% |
| Cash ConversionOCF / Net Profit | 1.35× | 2.40× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $239.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $68.9M | ||
| Q3 25 | $52.6M | $109.9M | ||
| Q2 25 | $35.6M | $73.7M | ||
| Q1 25 | $35.1M | $24.1M | ||
| Q4 24 | $29.0M | $34.2M | ||
| Q3 24 | $60.0M | $72.1M | ||
| Q2 24 | $69.1M | $36.2M | ||
| Q1 24 | $55.3M | $10.5M |
| Q4 25 | $24.6M | $63.0M | ||
| Q3 25 | $47.2M | $97.8M | ||
| Q2 25 | $25.0M | $64.9M | ||
| Q1 25 | $24.4M | $14.0M | ||
| Q4 24 | $16.6M | $29.0M | ||
| Q3 24 | $46.2M | $60.9M | ||
| Q2 24 | $63.1M | $27.6M | ||
| Q1 24 | $46.5M | $2.0M |
| Q4 25 | 13.4% | 21.7% | ||
| Q3 25 | 24.6% | 34.1% | ||
| Q2 25 | 14.3% | 21.9% | ||
| Q1 25 | 14.3% | 5.3% | ||
| Q4 24 | 8.9% | 11.7% | ||
| Q3 24 | 24.1% | 20.4% | ||
| Q2 24 | 34.6% | 10.6% | ||
| Q1 24 | 27.1% | 0.8% |
| Q4 25 | 4.5% | 2.0% | ||
| Q3 25 | 2.8% | 4.2% | ||
| Q2 25 | 6.1% | 3.0% | ||
| Q1 25 | 6.3% | 3.8% | ||
| Q4 24 | 6.7% | 2.1% | ||
| Q3 24 | 7.2% | 3.8% | ||
| Q2 24 | 3.3% | 3.3% | ||
| Q1 24 | 5.1% | 3.4% |
| Q4 25 | 1.35× | 2.40× | ||
| Q3 25 | 3.03× | 0.50× | ||
| Q2 25 | 1.15× | 2.83× | ||
| Q1 25 | 1.39× | 0.78× | ||
| Q4 24 | 0.76× | 1.46× | ||
| Q3 24 | 1.48× | 2.10× | ||
| Q2 24 | 1.82× | 1.24× | ||
| Q1 24 | 1.28× | 0.45× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
ESE
| US Government | $98.0M | 34% |
| Utility Solutions Group | $87.5M | 30% |
| RF Shielding And Test | $58.3M | 20% |
| Commercial | $45.8M | 16% |
| Related Party | $1.3M | 0% |
